Life Sciences / In-Vitro Diagnostics / Biomarker Detection Technology
Strategic Profile
The company operates a consumable-based revenue model providing recurring revenue and high margins as the installed base of Simoa instruments grows. The company primarily operates in neurology, oncology, immunology, and inflammation, with focus on selling to academic/governmental research institutions, pharmaceutical, biotechnology, and contract research companies through direct sales and distributors.
Cyborg Score Rationale
Quanterix generated revenue of $137.42 million in 2024, increasing 12.30% year-over-year, with growing strategic momentum in Alzheimer's and biomarker diagnostics. However, losses were -$38.53 million in 2024, 35.9% more than 2023, reflecting continued path to profitability challenges.
Top Insights
Quanterix appointed Everett Cunningham as President and CEO effective January 19, 2026, with company expecting to exceed revenue and cash guidance for full year 2025
The company announced FDA 510(k) submission for multi-analyte algorithmic blood test for Alzheimer's disease detection in February 2026
A landmark Nature study revealed Simoa p-Tau 217 assay enabled assessment of 11,000+ samples showing age-related increase in Alzheimer's disease neuropathology prevalence
Long-standing relationships with leading pharmaceutical companies and research institutions provide stable revenue stream, while collaborations enhance market reach and drive adoption of Simoa technology in new applications
Named Competitors
Digital Biomarkers — Established competitor in immunoassay and molecular diagnostics
Blood-Based Biomarkers — Major player in blood screening and diagnostic platforms
Immunoassay Platforms — Large-cap competitor in automated immunoassay systems
Recent Developments
(February 2026) FDA 510(k) submission for multi-analyte Alzheimer's disease blood test
(January 2026) New CEO appointment - Everett Cunningham; exceeded 2025 revenue and cash guidance
(November 2025) Board and leadership changes; landmark GFAP/NfL blood test study for multiple sclerosis monitoring
(November 2025) Landmark Nature study on Alzheimer's disease neuropathology published
Open the full interactive Quanterix Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.